낭성섬유증 폐질환
Cystic fibrosis lung disease: Current perspectives
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). These mutations alter the synthesis, processing, function, or half-life of CFTR, the main chloride channel expressed in the apical membrane of epithelial cells in the airway, intestine, pancreas, and reproductive tract. Lung disease is the most critical manifestation of CF. It is characterized by airway obstruction, infection, and inflammation that lead to fatal tissue destruction, which causes most CF morbidity and mortality. This article reviews the pathophysiology of CF, recent animal models, and current treatment of CF.
Abstract
Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). These mutations alter the synthesis, processing, function, or half-life of CFTR, the main chloride channel expressed in the apical membrane of epithelial cells in the airway, intestine, pancreas, and reproductive tract. Lung disease is the most critical manifestation of CF. It is characterized by airway obstruction, infection, and inflammation that lead to fatal tissue destruction, which causes most CF morbidity and mortality. This article reviews the pathophysiology of CF, recent animal models, and current treatment of CF.
참고문헌 (32)
- Riordan JR, "Identification of the cystic fibrosis gene : cloning and characterization of complementary DNA", Science, 245, pp.1066~1073 (1989)
- Welsh MJ, "The metabolic and molecular basis of inherited disease", pp.5121~5189 (2001), McGraw-Hill
- Stoltz DA, "Origins of cystic fibrosis lung disease", N Engl J Med, 372, pp.351~362 (2015)
- Moon HR, "Cystic fibrosis--a case presented with recurrent bronchiolitis in infancy in a Korean male infant", J Korean Med Sci, 3, pp.157~162 (1988)
- 안강모, "Cystic Fibrosis in Korean Children:A Case Report Identified by a Quantitative Pilocarpine Iontophoresis Sweat Test and Genetic Analysis", Journal of Korean Medical Science, 20(1), pp.153~157 (2005), 대한의학회
- Boucher RC, "Airway surface dehydration in cystic fibrosis : pathogenesis and therapy", Annu Rev Med, 58, pp.157~170 (2007)
- Cohen TS, "Cystic fibrosis : a mucosal immunodeficiency syndrome", Nat Med, 18, pp.509~519 (2012)
- Anderson MP, "Demonstration that CFTR is a chloride channel by alteration of its anion selectivity", Science, 253, pp.202~205 (1991)
- Quinton PM, "Cystic fibrosis : impaired bicarbonate secretion and mucoviscidosis", Lancet, 372, pp.415~417 (2008)
- Hobbs CA, "Does epithelial sodium channel hyperactivity contribute to cystic fibrosis lung disease", J Physiol, 591, pp.4377~4387 (2013)
- Chen JH, "Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia", Cell, 143, pp.911~923 (2010)
- Tuggle KL, "Characterization of defects in ion transport and tissue development in cystic fibrosis transmembrane conductance regulator(CFTR)-knockout rats", PLoS One, 9, pp.e91253~ (2014)
- Sun X, "Lung phenotype of juvenile and adult cystic fibrosis transmembrane conductance regulator-knockout ferrets", Am J Respir Cell Mol Biol, 50, pp.502~512 (2014)
- Itani OA, "Human cystic fibrosis airway epithelia have reduced Cl-conductance but not increased Na+ conductance", Proc Natl Acad Sci U S A, 108, pp.10260~10265 (2011)
- Pezzulo AA, "Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung", Nature, 487, pp.109~113 (2012)
- Hoegger MJ, "Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis", Science, 345, pp.818~822 (2014)
- Rogers CS, "Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs", Science, 321, pp.1837~1841 (2008)
- Bonvin E, "Congenital tracheal malformation in cystic fibrosis transmembrane conductance regulator-deficient mice", J Physiol, 586, pp.3231~3243 (2008)
- Meyerholz DK, "Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children", Am J Respir Crit Care Med, 182, pp.1251~1261 (2010)
- Chang EH, "Sinus hypoplasia precedes sinus infection in a porcine model of cystic fibrosis", Laryngoscope, 122, pp.1898~1905 (2012)
- Adam RJ, "Air trapping and airflow obstruction in newborn cystic fibrosis piglets", Am J Respir Crit Care Med, 188, pp.1434~1441 (2013)
- Fischer AJ, "Tracheomalacia is associated with lower FEV1 and Pseudomonas acquisition in children with CF", Pediatr Pulmonol, 49, pp.960~970 (2014)
- Schmidt BZ, "Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis : current perspectives", Clin Pharmacol, 8, pp.127~140 (2016)
- Haardt M, "C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation", J Biol Chem, 274, pp.21873~21877 (1999)
- Welsh MJ, "Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis", Cell, 73, pp.1251~1254 (1993)
- Varga K, "Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator(CFTR)by pharmacological chaperones", Biochem J, 410, pp.555~564 (2008)
- "2013 CF Foundation Patient Registry Annual Data Report to the Center Directors" (2014)[URL]
- McCormack J, "Daily versus weekly azithromycin in cystic fibrosis patients", Eur Respir J, 30, pp.487~495 (2007)
- Lands LC, "High-dose ibuprofen in cystic fibrosis : Canadian safety and effectiveness trial", J Pediatr, 151, pp.249~254 (2007)
- Pedemonte N, "Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening", J Clin Invest, 115, pp.2564~2571 (2005)
- Van Goor F, "Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules", Am J Physiol Lung Cell Mol Physiol, 290, pp.L1117~L1130 (2006)
- Dhooghe B, "Strategies in early clinical development for the treatment of basic defects of cystic fibrosis", Expert Opin Investig Drugs, 25, pp.423~436 (2016)